Abstract: TAK-063 is currently being developed to treat schizophrenia. In this study, we investigated the absorption, distribution, metabolism and excretion (ADME) properties of TAK-063 using several paradigms. Following oral administration of TAK-063 at 0.3 mg/kg, bioavailability of TAK-063 was 27.4% in rats and 49.5% in dogs with elimination half-lives of 3.1 hr in rats and 3.7 hr in dogs. TAK-063 is a highly permeable compound without P-glycoprotein (P-gp) or breast cancer resistance protein substrate liability and can be readily absorbed into systemic circulation via the intestine. TAK-063 can also cross the blood-brain barrier. TAK-063 was metabolized mainly by CYP2C8 and CYP3A4/5, while incubation with human liver microsomes produced the major human metabolite, M-I as well as several unknown minor metabolites. Metabolism of TAK-063 to M-I occurs through hydroxylation of the mono-substituted pyrazole moiety. In vitro, TAK-063 was observed to inhibit CYP2C8, CYP2C19 and Pgp with IC 50 values of 8.4, 12 and 7.13 lM, respectively. TAK-063 was primarily excreted in the faeces in rats and dogs with M-I as a predominant component. The pre-clinical data from these ADME studies demonstrate a favourable pharmacokinetic profile for TAK-063 with good brain distribution supporting the feasibility of targeting central nervous system regions involved in schizophrenia pathophysiology. TAK-063 has recently been investigated in a phase 2 clinical trial (NCT02477020).
Phosphodiesterase 10A (PDE10A) acts as an important regulator of signal transduction by degrading the second messengers cyclic adenosine monophosphate and cyclic guanosine monophosphate [1, 2] . PDE10A is preferentially expressed in the medium spiny neurons of the striatum, a region of critical importance for domains that are disrupted in patients with schizophrenia [3] [4] [5] .
Current treatments often do not adequately address the multifaceted clinical symptomatology of schizophrenia [6] . In addition, antipsychotics are associated with cardiometabolic disturbances and cardiovascular morbidity that worsen longterm outcomes [7] . Because of the shortcomings in current treatment options for schizophrenia, PDE10A inhibition by TAK-063 is being evaluated as a new therapeutic strategy.
TAK-063 is a potent and highly selective PDE10A inhibitor [8, 9] . Furthermore, TAK-063 has demonstrated pre-clinical efficacy in animal models of schizophrenia. TAK-063 produced dose-dependent antipsychotic-like effects in rodent models of induced psychosis [10] . In rodents, PDE10A inhibition by TAK-063 also improved cognitive functions impaired in schizophrenia [11] . TAK-063 exhibits a favourable safety profile in a rodent study [12] . To understand the mechanism of these efficacy and safety profiles of TAK-063, the absorption, distribution, metabolism and excretion (ADME) properties of TAK-063 were investigated.
In general, ADME properties using radiolabelled materials in animals and human beings are required for inclusion in the New Drug Application for new molecular entities. This report helps describe the disposition and elimination mechanisms of TAK-063 and its related metabolites in animal models and human beings and can be used to compare the exposure of TAK-063-related entities in animals used in the toxicity programmes during drug development with data from human studies and to investigate human-specific metabolite(s).
Here, we report the pre-clinical pharmacokinetic (PK) properties of TAK-063 including ADME. The results of the current study are useful in complementing the PK profile of TAK-063 delineated in the clinical programme.
Materials and Methods
Chemical and biological reagents. All reagents and solvents were of analytical grade or equivalent. TAK-063 (1- Concentrations of TAK-063 and M-I were analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total radioactivity in the plasma was determined by liquid scintillation counter (LSC).
Urine and faecal samples were collected separately from the intact rats treated with [
14 C]TAK-063 under dry ice-chilled conditions and room temperature in metabolic cages up to 168 hr after dosing. In addition, expired air was collected into a CO 2 -absorbent solution of 2-aminoethanol/2-methoxyethanol (1:2, v/v) at room temperature up to 24 hr after dosing. The total radioactivity in urine and faeces was determined by LSC.
For the BDC rat study, the common bile duct of rats was cannulated with polyethylene tubing (PE10, Becton Dickinson and Company, Franklin Lakes, NJ, USA) under anaesthesia with isoflurane. After efflux of bile was confirmed, a single dose of [ 14 C]TAK-063 (1 mg/kg) was given intraduodenally and the rats were housed in Ballman cages. Bile samples were collected under dry ice-chilled conditions, and urine and faecal samples were collected at room temperature during the 24 hr after dosing.
In vivo tissue distribution was determined after administration of [ 14 C]TAK-063 at a dose of 1 mg/kg to fed male albino and pigmented rats. At 1, 3, 8, 24 , 48 and 168 hr after administration of [ 14 C]TAK-063, the rats were killed and tissue was collected. Concentrations of tissue radioactivity were determined by the combustion method of radioactivity measurement.
To assess brain penetration of M-I, male rats received M-I intravenously at a dose of 0.1 mg/kg/h for a total of 4 hr. After 4 hr, the rats were killed and brains were excised to produce a 20% brain homogenate, which was analysed for M-I by LC-MS/MS. Dog studies. Pharmacokinetic, mass balance and metabolite profiling studies of TAK-063 were undertaken in male fed or fasted dogs. After oral or IV administration of TAK-063 and/or [ 14 C]TAK-063 to dogs, blood was collected from the cephalic vein at the following timepoints (oral): 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 32 and 48 hr, and (IV): 0.083, 0.167, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 32 and 48 hr. The blood was immediately cooled under ice-chilled conditions and centrifuged at approximately 1850 9 g at 4°C for 10 min. to obtain the plasma. Concentrations of TAK-063 and M-I were analysed by LC-MS/MS. The total radioactivity in the plasma was determined by LSC. A portion of the plasma samples was used for metabolite identification studies.
Urine and faecal samples were collected under dry ice-chilled conditions and room temperature, respectively, in separate amber glass vials up to 24 or 72 hr after dosing. The total radioactivity in urine and faecal samples was determined by LSC.
Permeability study of [
14 C]TAK-063 across Caco-2 cells. Caco-2 cells were cultured at 37°C in a 5% CO 2 incubator for 23 days to achieve cell layers sufficient to perform a permeability study to determine the absorption of TAK-063. The passage medium was composed of Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 9% foetal bovine serum (FBS; Invitrogen), 100 lM non-essential amino acids (Invitrogen), 2 mM Lglutamine (Invitrogen), 100 U/mL penicillin G (Invitrogen), 100 lg/ mL streptomycin (Invitrogen) and 250 ng/mL amphotericin B (Invitrogen). For analysis of apical (A) to basal (B) or basal (B) to apical (A) transport, the donor side of Caco-2 cells was incubated at 37°C in the presence of buffer containing 3 lM (PerkinElmer) . After a 1-to 2-hr incubation, samples were collected from the receiver side and total radioactivity was measured by scintillation counting. The permeation coefficient (P app ) was calculated according to the following equation:
where dQ/dt, A and C 0 represent the transport rate, membrane area and initial concentration of TAK-063 in the donor side, respectively.
The efflux ratio of P app was equal to the P app value for B to A transport (P app B?A ) divided by the P app value for A to B transport (P app A?B ), as in the following equation:
The inhibitory effect of TAK-063 on P-glycoprotein (P-gp) activity was also investigated in Caco-2 cell monolayers. The experimental conditions were similar to those of the permeability study. [ IC 50 values were calculated from the relationship between TAK-063 or quinidine concentration and the per cent of the control according to the following equation:
[I] is the concentration of TAK-063 or quinidine.
In 
R, C p and C f represent protein-binding ratio (%) of tested compound, concentration of tested compound in the spiked sample (dpm/mL) and concentration of tested compound in supernatant after ultracentrifugation (dpm/mL), respectively.
CYP reaction phenotyping studies. A study of CYP-expressing microsomes and correlation analysis between the elimination rates of TAK-063 or formation rates of metabolites and rates of metabolism of marker substrates using individual human liver microsomes from 16 donors (mixed) was conducted for CYP reaction phenotyping. [
14 C]TAK-063 (10 lM) was incubated with human liver microsomes (0.5 mg protein/mL) or CYP-expressing microsomes (100 pmol P450/mL) in 50 mM potassium phosphate buffer (pH 7.4) to a final volume of 300 lL. The reactions were initiated by adding a nicotinamide-adenosine dinucleotide phosphate (NADPH)-generating system (final concentration of 5 mM MgCl 2 , 5 mM glucose 6-phosphate, 0.5 mM b-NADP + and 1.5 units/mL glucose-6-phosphate dehydrogenase). After incubation at 37°C for 30 min. in a shaking water bath, the reaction was terminated by adding 150 lL acetonitrile. For CYP2C9-expressing microsomes, the incubation was conducted in Tris-HCl buffer (50 mM, pH 7.4) instead of potassium phosphate buffer. After centrifuging at 15009 g for 10 min., the supernatant was applied to LSC and high-performance liquid chromatography (HPLC) analysis. The HPLC conditions were conducted as described in the rat and dog studies sections with minor modifications in the gradient programme. Correlation analyses and calculation of the Pearson productmoment correlation coefficient were performed between the logarithmic metabolic rates of the respective CYP isoform-specific substrates and the logarithmic elimination amount of TAK-063 or the logarithmic formation amounts of M-I, and unidentified metabolites UK-1 and UK-2 with SAS System version 8.02. If the remaining CYP activity in the presence of TAK-063 (up to 20 lM) was 50.0% or less, the activity was analysed by Pharmacodynamic model 103 (Inhibitory effect E max model) using WinNonlin version 5.2.1 (Pharsight Corporation, Cary, NC, USA) to determine the concentration required to achieve 50% inhibition (IC 50 ). If the remaining CYP activity in the presence of the highest tested concentration of TAK-063 or M-I was greater than 50.0%, IC 50 was expressed as greater than the highest tested concentration of TAK-063 or M-I. For TAK-063, after treatment for 1 or 4 days, hepatocytes were rinsed with fresh medium and then incubated with phenacetin (100 lM, CYP1A2), bupropion (500 lM, CYP2B6) or testosterone (250 lM) in the CO 2 incubator at 37°C for 2 hr. After incubation, the medium for each well was stored at À80°C until analysis. Marker enzyme activities of CYP1A2 (phenacetin-O-deethylation), CYP2B6 (bupropion hydroxylation) and CYP3A4/5 (testosterone 6b-hydroxylation) were analysed by HPLC. After 3-day treatment with M-I, the hepatocytes were harvested to isolate RNA, which was analysed by quantitative real-time polymerase chain reaction to assess the effect of TAK-063 M-I on CYP1A2, CYP2B6 and CYP3A4 mRNA levels.
Enzyme induction ratios (%) for TAK-063 and M-I were calculated as follows: Metabolite identification study. Metabolite identification in dog plasma was performed with a Prominence HPLC system (Shimadzu Corporation, Kyoto, Japan) coupled to a hybrid mass spectrometer (LTQ Orbitrap, Thermo Fisher Scientific, Inc., Waltham, MA, USA) equipped with an electrospray ionization (ESI) interface system in a positive ion mode and online flow scintillation analyses (Radiomatic 505TR, PerkinElmer). Pooled dog plasma (3 hr after [
14 C]TAK-063 dosing) was extracted with 3 volumes of acetonitrile and centrifuged at 1500 9 g at 10°C for 10 min. The supernatant was evaporated to dryness under a stream of nitrogen gas at room temperature. The residue was dissolved in a 4:1 (v/v) mixture of the mobile phases (MP)-A, and MP-B (MP-A and MP-B are mixtures of 10 mM ammonium acetate [pH 4] and acetonitrile [9:1 and 1:9, by volume, respectively]). The sample was then subjected to LC/MS and online flow scintillation analyses. For separation of analytes, a Develosil C30 UG-5 column (5 lm, 250 x 4.6 mm i.d., Nomura Chemical Co., Ltd., Hinode-cho Seto, Japan) at a flow rate of 1.0 mL/min. was used. The column temperature was maintained at 40°C. The samples were eluted with the following gradients: the concentration of MP-B was initially increased from 10 to 50% over 35 min. and from 50 to 90% in 0.1 min., then held at 90% for 9.9 min. and finally cycled back to the initial conditions.
Metabolite profile studies. Metabolite profiles in plasma, brain, excreta and liver microsomes were elucidated by HPLC equipped with online RI detector. The preparation method for plasma samples and brain and faecal homogenates was similar to that described in the metabolite identification study with minor modification. Urine and bile samples were diluted with the mixture of MP-A and MP-B (9:1) under ice-chilled conditions at ratios of 1:1 and 1:4, respectively. After 1-min. vortex, the samples were centrifuged at approximately 1850 9 g at 10°C for 10 min. Each supernatant was then subjected to HPLC-RI analysis.
[
14 C]TAK-063 (10 lM) was incubated with liver microsomes (rats: 2 mg/mL; human beings and dogs: 0.5 mg/mL) obtained from rats, dogs or human beings. After a 30-min. incubation at 37°C, the reaction was terminated by adding a half volume acetonitrile. After vortex and centrifugation, the supernatant was injected into the HPLC system under conditions described in the metabolite identification study.
Quantification of TAK-063 and M-I in plasma and/or brain. Plasma concentrations of TAK-063 in rats and dogs were quantitated by LC-MS/MS using an Agilent 1100 HPLC system and TSQ Quantum Discovery MAX (Thermo Electron, Waltham, MA, USA) with ESI as an interface. The plasma samples (50 lL) collected from rats and dogs treated with TAK-063 were added to 10 lL of internal standard (IS) working solution and 10-lL aliquots of DMSO/methanol (1:9, v/v), followed by 400 lL distilled water. After vortex, the samples were applied onto a solid-phase extraction (SPE) plate previously equilibrated with 200 lL methanol and distilled water, successively. The SPE plate was then washed with 200 lL 5% methanol. The analytes were eluted twice with 50 lL of the elution solution, followed by the addition of 300 lL aliquots of 10 mM ammonium acetate. After mixing, 20 lL aliquots of the diluted eluates were injected into the LC-MS/MS. Chromatography was carried out using a CAPCELL PAK C18 MGII column (4.6 mm i.d. 9 150 mm, 5 lm) at 40°C and two mobile phases (50 mM ammonium acetate and acetonitrile) delivered at a flow rate of 1 mL/min. In the mass spectrometric analysis, analytes were detected via the selected reaction monitoring method. The monitoring ions of TAK-063 were m/z 429.1?217.1, and the calibration curve of TAK-063 ranged from 0.3 to 1000 ng/mL.
Concentrations of M-I in the plasma and brain of rats administered M-I (0.1 mg/kg/h for 4 hr) by IV infusion were quantitated by LC-MS/MS. The brain sample was prepared as follows: 10 lL acetonitrile/DMSO (100:1, v/v) was added to 50 lL of brain (20% homogenate) sample followed by addition of 10 lL of IS working solution and 100 lL methanol. After vortex and centrifugation (20,000 9 g for 5 min. at 4°C), 130 lL of supernatant was filtered (Ultrafree-MC, polyvinylidene fluoride, 0.22 lm pore filter unit, Millipore) by centrifugation (20,000 9 g for 5 min. at 4°C) and 100 lL of filtrate was mixed with 50 lL of 10 mM ammonium acetate. After vortex, 10 lL of sample was analysed by LC-MS/MS. Plasma sample preparation was similar to that of the brain samples with minor modifications. M-I was quantitated with an Agilent 1100 HPLC system and API4000 
Results

Pharmacokinetics.
The PK parameters of TAK-063 in rats and dogs after a single oral and IV administration are summarized in table 1. After oral administration at a single dose of 0.3 mg/kg, TAK-063 was moderately absorbed with time to reach the maximum observed plasma concentration (T max ) values of 2.0 and 3.5 hr in fed male rats and dogs, respectively. The oral absolute BA of TAK-063 was 27.4% in fed male rats and 49.5% in fed male dogs. After oral administration, the elimination half-life (T 1/2 ) values were 3.1 and 3.7 hr in the rat and dog, respectively. After IV administration to rats, the mean plasma clearance (CL p ) and volume of distribution at steady-state (Vss) were 122.8 mL/h/kg and 733.9 mL/kg, respectively. The CL p value was lower than the hepatic blood flow (3310 mL/h/kg) and the value of Vss was similar to total body water (668 mL/kg) in rats, suggesting that TAK-063 has a low hepatic extraction ratio and volume of distribution in rats. After IV administration to dogs, the mean CL p was 1229.4 mL/h/kg, which approached the hepatic blood flow (1850 mL/h/kg), indicating that TAK-063 has a high hepatic extraction ratio in dogs [13] . The value of Vss (2464.5 mL/kg) was approximately fourfold greater than total body water (604 mL/kg) in dogs, suggestive of moderate to high tissue distribution. Compared with rats, the shorter T 1/2 (1.6 hr) in dogs after IV administration is probably due to a higher CL p ( fig. 1 and table 1) .
Overall, systemic exposure of TAK-063 as measured by area under the plasma drug concentration-time curve (AUC) and peak plasma concentration (C max ) increased in an approximately dose proportional manner after oral administration to fed rats and dogs over a dose range of 0.3 mg/kg to 1.0 mg/kg. Food effect on the PK of TAK-063 was observed in dogs. Compared with data in fasted dogs after a single oral dose of 0.3 mg/kg, the C max and AUC 0-24 values in fed dogs were reduced by approximately 70 and 40%, respectively, and the T max value increased from 1 to 3.5 hr. A longer T 1/2 was also observed ( The inhibitory effect of TAK-063 on P-gp activity was also investigated in Caco-2 cell monolayers. TAK-063 decreased the P app efflux ratio of the P-gp substrate digoxin in a concentration-dependent manner with an IC 50 value of 7.13 lM (fig. 2) .
Distribution.
Tissue distribution in rats. TAK-063 was widely distributed throughout albino rat tissues after oral administration of a single dose of 1 mg/kg of [ 14 C]TAK-063, including the brain (table 3) . The concentrations of radioactivity attained their maxima at 3 hr after administration for all tissue compartments except for stomach (C max at 1 hr). After 3 hr, the highest concentration was found in the liver (1.584 lg equiv/g). The concentrations in all tissues decreased to low levels or below the limit of quantitation (LOQ) after 168 hr. A metabolite profile study indicated that TAK-063 was the major component in the rat brain (>99% of total radioactivity) at 3 hr after dosing. In addition, the study indicated that TAK-063 and/or its metabolites may have a weak affinity for melanin (data on file). M-I brain penetration was evaluated in rats in a separate study. After IV infusion of M-I for 4 hr at a dose of 0.1 mg/ kg/h, the M-I brain-to-plasma ratio ranged from 0.04 to 0.07, suggesting minimal brain penetration for M-I in rats. In comparison, the ratio for TAK-063 at 3 hr after oral administration of 14 [C]TAK-063 was approximately 1. (table 5) . TAK-063 mainly bound to HSA in human plasma. Plasma protein-binding ratios of TAK-063 were comparable to those of M-I in rats and dogs, whereas plasma protein binding of M-I in human plasma was higher than that of parent drug TAK-063 (˃99.6% versus 96.4%).
Metabolism.
The metabolism of TAK-063 to the metabolite M-I was postulated to occur by hydroxylation of the mono-substituted pyrazole moiety ( fig. 3) . The chemical structures of unchanged TAK-063 and M-I were identified by LC-MS/MS analysis as the mass spectra and HPLC retention time of TAK-063 and M-I in dog plasma coincided with those of the authentic standards.
In vivo metabolism. Profiling of plasma samples collected from rats or dogs treated with [ 14 C]TAK-063 at a single oral dose of 1 mg/kg indicated that TAK-063 was the major a Each point was calculated using the mean P app ratios. component, accounting for 95.2 and 71.4% of total radioactivity, respectively. On average, the plasma concentrations of M-I accounted for 11.2% of total radioactivity in dogs, but were below the LOQ at all timepoints examined in rats.
As shown in table 6, after oral administration to intact rats, 91.9% of dosed radioactivity was associated with faeces, with 4.7% being excreted via urine within 48 hr of administration. Unchanged TAK-063, M-I and other unidentified minor metabolites accounted for 41.5, 24.8 and 25.6% of the dose in faeces, and LOQ, 1.3% and 3.4% of the dose in urine, respectively. These minor metabolites were various conjugates of oxidative metabolites that were detected in urine, and a number of oxidative metabolites including PK-5 that were detected in faeces (fig. 4) . After intraduodenal administration to BDC rats, 37.8% of dose radioactivity was associated with bile. Unchanged TAK-063, M-I and other unidentified minor metabolites (various conjugates of oxidative metabolites) accounted for 0.3, 2.2 and 35.3% of the dose in bile (table 6), respectively.
After oral administration to dogs, 95.6% of dosed radioactivity was associated with faeces, with 1.6% excreted via urine within 24 hr of administration (table 6) . Unchanged TAK-063, M-I and various oxidative metabolites that were observed in urine and faeces accounted for 60.8, 18.4 and 16.5% of the dose in faeces, respectively (table 6). The amount of parent drug and M-I was less than 0.1% in the urine (table 6).
In vitro metabolism. Incubation of [
14 C]TAK-063 with human hepatic microsomes generated M-I and unidentified minor metabolites including UK-1 (structure unknown) and UK-2 (oxidative metabolite) ( fig. 4 ). Among these metabolites, M-I was the major metabolite in human beings as well as in animals. No human-specific metabolite was noted in human hepatic microsomes.
CYP reaction phenotyping.
As shown in fig. 5 , the CYP-expressing microsomal study suggested that CYP2C8, CYP2D6 and CYP3A4 were the major isoforms involved in the elimination of TAK-063 or formation of M-I, UK-I or UK-2. The correlation study indicated that elimination of TAK-063 most strongly correlated with CYP2C8 (r = 0.7502, p ≤ 0.01) and CYP3A4/5 activities (r = 0.7074, p ≤ 0.01), followed by CYP1A2 (r = 0.5814, p ≤ 0.05) (table 7). Formation of M-I and UK-1 strongly correlated with CYP2C8 activity (M-I: r = 0.7431, p ≤ 0.01; UK-1: r = 0.7629, p < 0.01). In addition, formation of M-I also correlated with CYP1A2 activity (r = 0.6205, p ≤ 0.05). Formation of UK-2 correlated with CYP2C19 (r = 0.6262, p ≤ 0.05) and CYP3A4/5 activities (r = 0.6824, p ≤ 0.05). There was no significant correlation between the elimination of TAK-063, formation of M-I, UK-1 and UK-2 or any other marker enzyme activity (table 7) .
CYP inhibition and induction. TAK-063 inhibited CYP2C8 and CYP2C19 activities with IC 50 values of 8.4 and 12 lM, respectively (table 8) . TAK-063 did not significantly inhibit CYP1A2, CYP2B6, CYP2C9, CYP2D6 or CYP3A4/5 activities, with IC 50 values >20 lM for all of these enzymes. As seen in table 8, M-I did not significantly inhibit any CYPs tested (IC 50 >10 lM). In addition, neither TAK-063 up to 20 lM nor M-I exhibited significant time-dependent inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activities. Overall, TAK-063 and M-I exhibited minimal inducing effects on CYP1A2, CYP2B6 or CYP3A4/5 activities in vitro with average induction ratios <19% for TAK-063 and ≤8% for M-I (table 9) . For CYP2B6, in the three-day treatment with 20-lM TAK-063, the induction ratio was 21% in one donor. In the two-day treatment with 20-lM TAK-063, the induction ratios of CYP2B6 in three donors ranged from 20 to 23%.
Excretion.
After oral administration of [
14 C]TAK-063 to fed male rats and dogs, the mean total recovery of radioactivity at 168 hr after dosing was 97.3 and 97.9%, respectively (table 10) . Faeces and urine accounted for 92.6% and 4.7% of the dose in rats, and 96.1 and 1.9% of the dose in dogs, indicating that the primary route of elimination of drug-derived radioactivity was via faeces. Unchanged TAK-063 accounted for <1% of the dose in urine and/or bile of rats and dogs, suggesting that urinary and/or biliary excretion of TAK-063 is minimal. After a single oral dose of [ 14 C]TAK-063 at 1 mg/kg, the total Table 6 . Mean levels of TAK-063 and M-I in the excreta of rats and dogs after a single oral dose of [ LOQ, below the lower limit of quantification; M-I, TAK-063 metabolite. 1 Other unknown minor metabolites. 2 For rats, data are expressed as the mean and standard deviation (n = 3, urine and faeces and n = 4, bile). For dogs, each value represents the mean AE standard deviation (n = 4). a Each bar represents a mean value of two samples.
recovery of radioactivity in intact rats and dogs was completed (>97% of the dose) at 168 hr after dosing and most of the radioactivity was recovered within 24 hr in rats (82.5% of the dose) and 48 hr in dogs (96.1% of the dose) (table 10 ). In addition, no radioactivity was detectable in any expired air samples collected. After a single intraduodenal dose of [
14 C]TAK-063 (1 mg/kg) to BDC rats, the recovery of radioactivity at 24 hr after dosing was 97.8% of the dose, and 37.8, 3.3 and 56.8% of total radioactivity was excreted into bile, urine and faeces, respectively (table 10). These findings indicate that approximately 40% of the dose was absorbed in BDC rats.
Discussion
In the present study, pre-clinical ADME properties of TAK-063 were characterized in animals, and these properties were subsequently studied in human beings. TAK-063 exhibited a favourable profile for efficacious brain tissue distribution and exposure in rats. After oral administration, TAK-063 was moderately absorbed in fed male rats and dogs and was highly permeable in intestinal cell assays while showing no P-gp or BCRP liability. The result is consistent with a previous report, which demonstrated that TAK-063 effectively crossed the blood-brain barrier and increased second messenger concentrations in the mouse striatum [9] .
TAK-063 is characterized as a low clearance compound with a small volume of distribution in rats, but a high clearance compound with a moderate to high volume of distribution in dogs. These differences could be explained by higher plasma protein binding of TAK-063 in rats (>99%) than in dogs and human beings (95-96%). In a phase 1 clinical study of safety, tolerability and PK, TAK-063 exposure increased with dose within the 3 mg to 1000 mg dose range [14] . Clearance (CL/F) and volume of distribution (Vz/F) of TAK-063 also increased with dose, ranging from 14.0 to 232.0 L/h and from 407 to 5570.7 L, respectively [14] . The rat tissue distribution study indicated that radioactivity was distributed rapidly into tissues including the brain after oral administration of [
14 C]TAK-063. The ratio of brain-to-plasma TAK-063 was approximately 1 at 3 hr after dosing. In a human [ 11 C]T-773 PET study of PDE10A binding after TAK-063 oral administration, TAK-063 bound PDE10A in a plasma concentrationdependent manner [15] . These data demonstrate that TAK-063 was well distributed in the brains of animal models and human beings.
TAK-063 is mainly metabolized to M-I by hydroxylation of the mono-substituted pyrazole moiety. In addition, low levels of miscellaneous oxidative metabolites and their conjugates were detected in rats and dogs. Approximately 20-30% of the dose was eliminated as M-I via faeces and urine in rats and dogs treated with [
14 C]TAK-063, suggesting that the formation of M-I is one of the primary elimination pathways of TAK-063, with no difference in species noted. However, exposure levels of M-I were much lower than those of parent drug TAK-063 in dogs and rats. In contrast, M-I in human beings showed similar PK properties to TAK-063, with M-I-to-parent ratios of approximately 1 for C max , AUC (0-tlqc) and AUC (0-inf) (Tsai et al. 2016) . Interestingly, plasma protein binding of M-I is higher than TAK-063 (≥99% versus 96%, table 5), suggesting that the free fraction of TAK-063 is significantly higher than that of M-I in human plasma, although M-I-to-parent ratios were approximately 1. From a pharmacological point of view, the contribution of M-I in human beings is expected to be low despite showing similar pharmacological potency to unchanged TAK-063 in vitro. One reason led us to this conclusion. The brain distribution of M-I was confirmed after intravenous administration to rats, but the brain-to-plasma concentration ratio of M-I (K p = 0.014) was markedly lower than that of TAK-063. The correlation and CYP-expressing microsomal studies suggested that metabolism of TAK-063 is mediated by multiple CYPs. CYP2C8 and CYP3A4/5 appear to be the major metabolizing enzymes of TAK-063. TAK-063 inhibited CYP2C8, CYP2C19 and P-gp activities with IC 50 values of 8.4, 12 and 7.13 lM, respectively. Thus, these findings suggest that potential is low for TAK-063 inhibition of CYP2C8, CYP2C19 and P-gp.
After oral administration of [ 14 C]TAK-063 to rats and dogs, recovery of administered radioactivity was nearly complete (>97% of the dose), with >92% of the dose being excreted into faeces in both species. The concentrations of unchanged parent drug were below the lower limit of quantification in rat and dog urine, and <1% of the dose in rat bile, suggesting negligible importance of urinary and biliary excretion of TAK-063 in both species. This was in agreement with the low renal clearance of TAK-063 (CL r <7 mL/h) observed in a phase 1 study of TAK-063 at a dose range of 3 to 1000 mg (Tsai et al. 2016) . Unchanged TAK-063 accounted for 41.5 and 60.8% of the dose in faeces of fed rats and dogs, respectively, after oral administration, indicating that TAK-063 may have poor solubility. A food effect on the PK of TAK-063 was observed in dogs as drug absorption could be reduced by approximately 50% through co-administration with food in these species.
Pre-clinical data from these ADME studies demonstrate a favourable pharmacokinetic profile in animals for TAK-063 including wide distribution in the brain and other organs and targeting CNS domains involved in schizophrenia 2 Enzyme activities and mRNA were assayed for TAK-063 (two-or three-day treatment) and M-I (three-day treatment), respectively. 3 0 = 0.1% DMSO. 4 Omeprazole 50 lM was used as positive control of CYP1A2. 5 Phenobarbital at 1000 and 750 lM was used for TAK-063 and M-I assays, respectively. 6 Rifampin at 10 and 20 lM was used for TAK-063 and M-I assays, respectively. Only CYP3A4 was determined for the mRNA assay. 
